Vaginal Estradiol Absorption and Clinical Implications

Systemic Absorption and Safety

Vaginal estradiol can increase circulating estradiol levels within 2 weeks of use, particularly concerning for women on aromatase inhibitors where it may reduce treatment efficacy 1, 2
Low-dose vaginal estrogen formulations are generally thought to be safe with minimal systemic absorption, showing no concerning safety signals for stroke, venous thromboembolism, invasive breast cancer, colorectal cancer, or endometrial cancer in large prospective studies of over 45,000 women 3, 4

For women with hormone-sensitive conditions, such as breast cancer, the variable systemic absorption of vaginal estradiol raises legitimate concerns 1
Estriol-containing preparations may be preferable for women on aromatase inhibitors since estriol is a weaker estrogen that cannot be converted to estradiol, though it still undergoes vaginal absorption 1, 2

Transdermal systemic agents are typically preferred over vaginal for women with cardiovascular disease to minimize thrombotic factor activation 3